The development of the aqueous cream formulation of CAL/BDP, approved for plaque psoriasis in 2020, was a “big deal” because until then, the pH incompatibility of the two active ingredients ...

who continues to use the creams and ointments fairly often. Alternating topical therapies is another option for patients with mild/moderate psoriasis. "I'm usually going with high-potency topical ...

Karishmma Chawla, a Functional Medicine & Lifestyle Educator, explains, “Food is the most intimate part of our body. It ...

Optimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective measures, particularly the Psoriasis Area and Severity Inde ...

Approximately 35 million individuals in the U.S. suffer from atopic dermatitis and psoriasis, highlighting a substantial market opportunity for ZORYVE products. Recognition of ZORYVE cream for ...

like over-the-counter emollients and corticosteroid creams, are often considered first-line options for most types of psoriasis because they target skin symptoms without the side effects of oral ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.

Avoid fire, flame, and smoking during and immediately following application. The most common adverse reactions (≥1%) for ZORYVE cream 0.3% for plaque psoriasis include diarrhea (3.1%), headache (2.4%) ...

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

Detailed price information for Arcutis Biotherapeutics Inc (ARQT-Q) from The Globe and Mail including charting and trades.